Vical: Leerink Swann Healthcare Conference (Vical) - Feb 15, 2013 - "Allovectin Phase 2 Trial (N=127)"; "Open-label, multi-center, single arm study"; "Stage III (52%) or IV (48%) metastatic melanoma; "≦ M1b disease (no brain or liver mets) -normal LDH"; "Demonstrated safety and efficacy"; "No withdrawals for toxicity or adverse events"; "No grade 3 or 4 drug-related adverse events"; "11.8% objective response rate (RECIST); "18.8 months median overall survival"; ">60% of the subjects did not complete more than 1 treatment cycle"
P2 data • Melanoma
|